Recent News & Events

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
Chimeron Recipient Innovative Concept Award
Press Releases

Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development

Philadelphia, PA – Chimeron Bio, a Philadelphia-headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation…

900 900 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award
Press Releases

Chimeron Bio recognized by MilliporeSigma as a finalist in the Advance Biotech Grant Award

Philadelphia, PA – Chimeron Bio, a next generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its…

750 750 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors
Press Releases

Chimeron Bio Appoints Antonin de Fougerolles to its Board of Directors

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™…

300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Welcomes Kevin Heyeck as New CEO
Press Releases

Chimeron Bio Welcomes Kevin Heyeck as New CEO

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™…

300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
Press Releases

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Philadelphia, PA and College Station, TX – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed…

206 206 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine
Press Releases

Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM…

300 300 Chimeron Bio | Advancing Genetic Medicine
Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis
Press Releases

Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis

Philadelphia, PA – Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan…

625 625 Chimeron Bio | Advancing Genetic Medicine
Close